GLP-1 Side Effects By Week: Tracking Onset, Peak, And Resolution Through Titration

GLP-1 receptor agonists (semaglutide, tirzepatide) titrate up over approximately 5 months, with dose escalation every 4 weeks. Side effects cluster predictably around dose escalations. The first 1-2 weeks after each step-up typically show the worst symptoms, which resolve over 1-3 weeks as the body adjusts. Tracking side effects week by week reveals two important patterns: (1) whether the current dose is well-tolerated (symptoms resolving within 1-3 weeks suggests good tolerance) and (2) whether the next titration step is appropriate (persistent symptoms beyond week 3 of a dose suggests the body is not adjusting, often indicating the previous step was too aggressive). Documentation also makes provider visits productive by replacing vague answers ("how have things been since last visit") with a precise timeline showing dose changes, symptom intensity, and resolution. The Dosed app supports this pattern with daily logging during titration weeks and weekly summary at steady state, exporting to a single PDF for provider visits. This content is for educational and tracking purposes only and does not constitute medical advice.

Semaglutide titration is the most-documented schedule. A representative week-by-week side-effect pattern (individual variation is high — always work with a qualified healthcare provider): Weeks 1-4 (0.25 mg starter dose): - Week 1: Mild nausea (peak typically 24-72 hours post-injection), early satiety appears within days, mild constipation possible - Week 2: Nausea typically resolving, appetite suppression establishing - Week 3-4: Steady state at this dose, minimal symptoms in most individuals Weeks 5-8 (0.5 mg first step-up): - Week 5 (post-escalation): GI symptoms return for many — nausea peaks at 24-72 hours post-injection, may persist 5-7 days - Week 6: Symptoms resolving in most; if persisting strongly, consider provider discussion - Week 7-8: Steady state Weeks 9-12 (1.0 mg second step-up): - Week 9: Similar pattern — nausea, possibly constipation, occasional GI cramping - Week 10-12: Adaptation Weeks 13-16 (1.7 mg third step-up): - Week 13: Side effects may be more pronounced at higher doses; closer attention to log details - Week 14-16: Typically improves Week 17+ (2.4 mg max dose for Wegovy / 2.0 mg max for Ozempic): - Week 17-18: Initial adjustment; some individuals stop here if effective at lower dose - Long-term steady state Side-effect frequency declines with each successful step-up in most people, although a minority experience worsening with each escalation. The pattern itself is informative — if escalations are well-tolerated, future ones likely will be too; if each escalation produces severe symptoms, the schedule may need slowing.

Nausea is the most common GLP-1 side effect. Onset is typically within 24-72 hours of injection day. Peak intensity is usually day 2-3 post-injection. Resolution occurs over 24-48 hours after the peak. Typical pattern at a new dose: - Day 1 (injection day): Mild to no nausea - Day 2: Moderate nausea — peak intensity - Day 3: Moderate, still elevated - Day 4: Improvement begins - Day 5-7: Mostly resolved - Week 2 of dose: Often minimal nausea; body has adapted - Week 3+ of dose: Steady state, minimal symptoms Documentation pattern: rate nausea 0-10 daily for the first 14 days of each new dose. The Dosed daily-logging template includes a single nausea slider (0 = none, 10 = severe). Track time-of-day patterns (some report worst morning, others evening) and food-related patterns (heavy/fatty meals worsen). Mitigation strategies that some individuals find helpful (discuss with healthcare provider): - Smaller, more frequent meals - Avoiding heavy, greasy, or spicy foods on days 2-3 post-injection - Ginger, peppermint tea, or other anti-nausea foods (no clinical trials specific to GLP-1) - Adequate hydration - Injection timing — some find specific days work better (e.g., Sunday injection to have peak symptoms on a non-work day) When to contact healthcare provider: - Nausea persists strongly into week 3 of a dose - Vomiting prevents fluid intake (dehydration risk) - Persistent or severe abdominal pain (especially radiating to back — pancreatitis warning) - Symptoms worsen despite mitigation strategies Documentation captures these triggers automatically: the Dosed pattern view shows nausea intensity by week, making escalating vs resolving patterns visible at a glance.

GLP-1 medications slow gastric emptying, which produces a broader GI footprint than nausea alone. Constipation. Most common GI complaint after nausea. Onset: gradually over 1-2 weeks of starting (or after dose escalation). Pattern: persistent rather than acute. Mitigation: increased hydration (often inadequate when appetite is suppressed), fiber intake (foods or supplements), gentle exercise, possibly over-the-counter stool softeners (discuss with provider). Documentation: track bowel-movement frequency weekly. Pattern of <3 movements per week warrants provider discussion. Diarrhea. Less common than constipation but reported by some individuals. Often occurs after constipation has been managed too aggressively (over-supplementation with stool softeners), or as an idiosyncratic response. Track frequency and severity. Bloating. Common feeling of abdominal fullness or distention. Related to slowed gastric emptying. Onset: within days of starting; typically improves slowly over 2-4 weeks. Track 0-10 daily during titration weeks. Gastroparesis. Severe slowing of stomach emptying with food retention. Symptoms: persistent fullness, food coming up hours after eating, severe bloating. Distinguished from typical GLP-1 GI effects by severity and persistence. Requires healthcare provider attention and possibly dose adjustment. Documentation pattern: a simple GI severity score (0-10) plus a constipation frequency tracker (movements per week) captures most clinically relevant GI patterns. The Dosed app tracks these alongside the nausea log, so the full GI picture is visible together. Food-related strategies: smaller meals, less fatty/greasy food, slower eating, avoid lying down immediately after eating. Many people report these adjustments make a meaningful difference. Hydration is universally helpful for constipation.

Beyond GI symptoms, GLP-1s can affect energy and cognition. These effects are less documented in trials but commonly reported by users. Fatigue. Reported by some individuals, especially in the first 4 weeks. Possible mechanisms: reduced food intake (caloric deficit), GI symptoms affecting sleep, direct GLP-1 effects on central nervous system not fully understood. Pattern: tends to peak in week 1 of dose escalation, resolves over 1-2 weeks. Documentation: 0-10 energy rating daily during titration weeks. If chronic fatigue persists beyond week 4 of a dose, discuss with provider — could indicate hypothyroidism, anemia, or inadequate nutrition during reduced intake. Sleep. Some individuals report sleep disruption — both insomnia and excessive sleepiness. Mechanism unclear. Often resolves as body adjusts. Documentation: sleep quality 0-10 and duration daily. Cognitive ("brain fog"). Less commonly reported. Distinguish from fatigue. May relate to caloric deficit during reduced intake. Generally resolves with body adjustment. Food thoughts and appetite. The primary therapeutic effect — appetite suppression and reduced food preoccupation. Document this as a positive: 0-10 appetite rating where 10 = strongest suppression. Tracking this validates the therapy is working and shows the trajectory over time. Mood. GLP-1s have been investigated for mood effects (both positive and concerning). Most individuals report neutral or slight positive mood change with successful weight management. Some report increased anxiety, particularly early in treatment. New or worsening depression with suicidal thoughts is a boxed warning consideration — contact provider immediately. Documentation pattern: a daily 5-axis check (nausea, GI severity, energy, mood, appetite) during titration weeks provides a comprehensive picture. The Dosed daily template captures this in 30 seconds.

Most GLP-1 side effects are GI and resolve. A small subset requires immediate provider attention. Pancreatitis. Severe persistent abdominal pain, often radiating to the back. Different character from typical GLP-1 nausea — more severe, more persistent, often with fever or vomiting. Risk slightly elevated with GLP-1 use, though absolute incidence is low. Documentation pattern: any persistent abdominal pain >24 hours that does not respond to typical mitigation → contact provider. Gallbladder issues. GLP-1-associated cholelithiasis (gallstones) and cholecystitis. Risk elevated with rapid weight loss. Symptoms: right upper quadrant pain, often after fatty meals, possible nausea/vomiting, possible jaundice. Document any right-sided abdominal pain. Thyroid concerns. Medullary thyroid cancer (MTC) — boxed warning. Contraindicated in personal or family history of MTC and in multiple endocrine neoplasia type 2 (MEN2). Animal studies showed thyroid tumor risk; human data are less clear. Document baseline thyroid history at start; report any neck lumps or hoarseness. Severe dehydration. From severe nausea/vomiting/diarrhea preventing fluid intake. Especially concerning in elderly, kidney disease, or diabetic patients (increased acute kidney injury risk). Document fluid intake during severe symptom days. Hypoglycemia. GLP-1 monotherapy rarely causes hypoglycemia. Risk is elevated when combined with sulfonylureas (glipizide, glyburide) or insulin. Document blood glucose if combination therapy. Allergic reactions. Rare. Local injection-site rash is common and usually mild; systemic allergic reactions (rash, swelling, breathing difficulty) require immediate medical attention. Red-flag documentation rule: anything that does not fit the typical pattern (intensity > typical, duration > 3 weeks, unusual location like back pain or right-sided pain, systemic symptoms like fever) should be flagged for provider review at the next visit or sooner if severity is high. The Dosed app marks these as red-flag entries.

A clean weekly summary turns a typical provider visit ("how have you been?") into a productive review. The Dosed weekly summary export combines all daily logs into a single readable document. Weekly summary structure (auto-generated from daily logs): - Current dose and week number on this dose - Average GI severity (calculated from daily 0-10 ratings) - Average energy level - Average appetite suppression - Bowel movement frequency this week - Hours of sleep per night (average) - Any flagged days (red-flag entries above threshold) - Notes (free text from daily entries) Monthly summary adds: - Weight change for the month - Body measurements if tracked - Lab values from any draws (HbA1c, lipid panel, kidney function) - Side-effect intensity trend across weeks - Adherence rate (any missed doses?) For provider visits, the Dosed PDF export generates: - Complete titration history (date of each dose change) - Side-effect intensity-by-week chart - Weight progression (if integrated) - Any flagged red-flag entries with dates - Notes from injection day diary - Current medications list (combined with non-GLP-1 medications if tracked) Provider visit conversation flow with the PDF: 1. Show titration progress chart 2. Highlight any flagged red-flag entries for discussion 3. Show side-effect trend (improving, stable, worsening) 4. Show weight or other primary outcome trend 5. Discuss adherence and any missed doses 6. Provider makes decision about next titration step The goal is not to replace clinical judgment — it is to give the provider precise, organized data so the clinical judgment can be informed. Provider time is limited; well-documented patients get better attention.

Tracking side effects week by week across a 5-month titration is data-heavy but pays off in cleaner provider visits and clearer self-awareness of patterns. Dosed is built for this specific workflow. The calendar view distinguishes titration weeks (where daily logging is encouraged) from steady-state weeks (where weekly summary suffices). The daily template captures the 5-axis check (nausea, GI severity, energy, mood, appetite) in under a minute. The pattern view shows side-effect intensity by week, making escalation or resolution patterns visible. The export function generates a single PDF combining titration history, side-effect trends, weight progression, and any flagged red-flag entries — for provider visits. Always work with a qualified healthcare professional. This content is for educational and tracking purposes only and does not constitute medical advice.